| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Nov 24, 2009
Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl...
- Nov 16, 2009
Eisai Inc. today announced that LUSEDRA™ (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution,...
- Nov 11, 2009Eisai Employees, in Cooperation with the Foundation for Hospital Art, Create Artwork to Help Improve the Lives of Patients and Families
Eisai Inc. today announced that it has donated more than 80 pieces of artwork, created by its employees, to hospitals across the United States. The multi-panel murals were created by more than...
- Oct 30, 2009Eisai Plans to Submit Marketing Authorization Applications for Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer
Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced...
- Oct 29, 20092009 C.A.R.E. (Commitment to Alzheimer's. Recognition of Excellence.) Pharmacy Award Acknowledges Excellence in Alzheimer's Disease Education and Patient Care
Eisai Inc. and the Alzheimer's Association announce today that Heather Greene, PharmD is the recipient of the 2009 C.A.R.E. Pharmacy Award. (Photo: http://www.newscom.com/cgi-bin/prnh/20091029/NY00986
- Oct 28, 2009
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Centocor Ortho Biotech Inc. for development and commercialization of an antibody...
- Sep 24, 2009
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced that it has reached a comprehensive agreement with Pfizer Inc. (Headquarters: New York, CEO and Chairman of...
- Sep 24, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in...
- Sep 23, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, announced today that it was awarded $843,289 in funding from the National Institutes of Allergy and Infectious Diseases...
- Jul 15, 2009
Morphotek , Inc., a subsidiary of Eisai Corporation of North America, and Cancer Innovations, Inc. (CII), a privately held biotechnology company specializing in the development of oncology...
- Jul 8, 2009
Eisai Corporation of North America today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's supplemental new drug application (sNDA) for an...
- Jul 2, 2009
Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are...
- Jul 1, 2009
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced a research collaboration agreement with Synageva BioPharma Corporation to express and develop therapeutic...
- Jun 9, 2009Antibody Targets Endosialin, a Protein Widely Expressed on Tumors and Tumor Blood Vessel Cells
Morphotek®, Inc., a subsidiary of Eisai Corporation of North America, announced that the U.S. Food and Drug Administration (FDA) cleared its investigational new drug (IND) application to study...
- Jun 1, 2009Eisai Inc. and the Alzheimer's Association Support Award to Recognize Critical Role of Pharmacists in Alzheimer's Care
Eisai Inc., in coordination with the Alzheimer's Association, calls on individuals with Alzheimer's disease and their caregivers across America to nominate local pharmacists for the 2009 C.A.R.E....